Rajagopalan R, Anderson R
Glaxo Dermatology, Glaxo Wellcome, Inc., Research Triangle Park, NC 27709, USA.
Am J Contact Dermat. 1997 Dec;8(4):215-21.
A dermatology-specific quality-of-life instrument has been created and validated for its sensitivity, reproducibility, content, and construct validity. This instrument was used in an observational prospective study that evaluated the cost-effectiveness of patch testing in patients with contact dermatitis and suspicion of allergic component.
This multicenter, prospective, observational study was designed to study the various direct and indirect costs associated with diagnosis and treatment of suspected allergic contact dermatitis and the benefits of diagnosis with and without patch testing. The costs and benefits of various methods of diagnosis are evaluated to determine if patch testing is more cost-effective as a diagnostic method. One of the outcomes evaluated was the quality of life of the participants in the study and the impact of patch testing on this cohort.
A total of 567 subjects were enrolled to obtain evaluable data from at least 500 subjects from ten study centers; the investigators were chosen so as to obtain a mix of stratified degrees of usage of patch testing. Data were collected on demographics, physical characteristics, history of disease, visits to physicians, and, to evaluate costs, the use of resources such as drugs, nondrug substances, and services; other outcome data collected were on physician evaluation of improvement, confirmation of diagnosis, physician opinion of the disease management, and patient evaluation of dermatology-specific quality of life (DSQL), and pertinent economic factors. Only 6-month and 12-month follow-up visits were mandatorily scheduled according to the protocol; however, participants and providers were free to arrange additional visits as deemed necessary for health care.
This report focuses on the evaluations at the 6-month follow-up. There are completely evaluable data on pharmacoeconomics and DSQL for 431 patients. About 43% were patch tested, and the rest were diagnosed using the information from history and physical examinations. There was significantly better improvement in each of the DSQL domains in patch tested subjects compared with non-patch-tested subjects. In addition, patients treated in "low" use clinics had lower quality of life at 6-month follow-up than those treated in "high" use clinics.
Patch testing helps to diagnose the etiology of contact dermatitis early and treat the disease before it becomes chronic, thus reducing resources used and improving patient quality of life considerably.
一种针对皮肤科的生活质量评估工具已被研发出来,并在敏感性、可重复性、内容及结构效度方面得到验证。该工具被用于一项前瞻性观察性研究,评估斑贴试验在接触性皮炎且怀疑有过敏成分患者中的成本效益。
这项多中心、前瞻性、观察性研究旨在探讨与疑似过敏性接触性皮炎诊断和治疗相关的各种直接和间接成本,以及斑贴试验与非斑贴试验诊断的益处。评估各种诊断方法的成本和效益,以确定斑贴试验作为一种诊断方法是否更具成本效益。评估的结果之一是研究参与者的生活质量以及斑贴试验对该队列的影响。
共招募了567名受试者,以便从十个研究中心至少500名受试者中获取可评估数据;选择研究人员时,要涵盖不同分层程度的斑贴试验使用情况。收集了人口统计学、身体特征、疾病史、就诊情况的数据,为评估成本,还收集了药物、非药物物质和服务等资源的使用情况;收集的其他结果数据包括医生对病情改善的评估、诊断的确认、医生对疾病管理的意见,以及患者对皮肤科特定生活质量(DSQL)的评估,还有相关经济因素。根据方案,仅强制安排6个月和12个月的随访;然而,参与者和医疗服务提供者可根据医疗保健需要自由安排额外的就诊。
本报告重点关注6个月随访时的评估。有431名患者的药物经济学和DSQL的完整可评估数据。约43%的患者接受了斑贴试验,其余患者根据病史和体格检查信息进行诊断。与未进行斑贴试验的受试者相比,进行斑贴试验的受试者在DSQL的各个领域都有显著更好的改善。此外,在“低”使用量诊所接受治疗的患者在6个月随访时的生活质量低于在“高”使用量诊所接受治疗的患者。
斑贴试验有助于早期诊断接触性皮炎的病因,并在疾病变为慢性之前进行治疗,从而大大减少资源使用并显著提高患者生活质量。